Last 28.05.2018 the European Commission published a Proposal of Regulation to modify Regulation No. 469/2009 on Supplementary Protection Certificates for medicaments. Basically, the proposal contemplates that, for SPCs granted
News & Events
Our next events
It seems we can’t find what you’re looking for.
Our IP Blog
Spherium Biomed announced on May 17, 2018 that it has obtained positive results with its new drug Mucomel® in a phase I/IIa clinical trial for the
This phase IIa clinical study in paediatric and adult patients with mild to moderate atopic dermatitis is designed as a proof-of-concept, multi-centre, randomised, double-blind, vehicle-controlled
Spherium Biomed has recently signed a licensing agreement with Simini Technologies from Ontario (Canada) to develop veterinarian applications based on the Spherium’s proprietary topical cyclosporine (SP14019).
We are pleased to announce that Jose Miguel Lissén has joined ABG IP as partner in charge of our new Legal & Litigation department. José Miguel Lissén is a lawyer and
Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), receives approval
We are very proud to announce that on 8 March 2018 ABG IP received the“Patent Prosecution Firm of the Year” award for Spain at the 14th Annual Managing Intellectual Property (MIP)
“Setting up and management of innovative companies”, Dr. Pablo Calvo, European Patent Attorney and Partner at ABG’s electromechanical department will participate in the course to be held
As of 1 March 2018, a validation agreement between the EPO and the Government of the Kingdom of Cambodia will enter into force, by which